Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
Hematol., Transfus. Cell Ther. (Impr.)
; 43(2): 191-200, Apr.-June 2021. tab, ilus
Artigo
em Inglês
| LILACS
| ID: biblio-1286684
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation.In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels very high, high, intermediate and low).Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist. As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician's discretion.The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Meta 3.5 Prevenção e tratamento do consumo de substâncias psicoativas
Base de dados:
LILACS
Assunto principal:
Proteínas Tirosina Quinases
/
Doenças Cardiovasculares
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Fatores de Risco de Doenças Cardíacas
Tipo de estudo:
Estudo de etiologia
/
Guia de prática clínica
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Centro Paulista de OncologiaGrupo Oncoclínicas do Brasil/BR
/
HEMORIO/BR
/
Hospital Santa Marcelina/BR
/
Instituto do Câncer do Estado de São Paulo/BR
/
Pontifícia Universidade Católica de Campinas/BR
/
Universidade Federal de Ciências da Saúde de Porto Alegre/BR
/
Universidade Federal do Paraná - UFPR/BR
/
Universidade de São Paulo - USP/BR